BioMedNewsBreaks

WednesdaySep 21, 2022 11:50 am

BioMedNewsBreaks — GATC Health Corporation Releases Report on Recent Analysis Showing New Platform Performs 11x Better Than Industry Standard

GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using its proprietary upgraded version 2.0 of its drug-discovery artificial intelligence (“AI”) platform, is reporting on its recently completed analysis. According to the release, the company’s upgraded drug-discovery platform forecasts drug-candidate success rate with 88% accuracy; the platform also predicts drug-failure rates with 84% accuracy. Biopharma companies can potentially save billions of dollars using the new offering, the company observed. The report provides further validation of the accuracy of GATC Health’s newly launched platform, which is designed to study and predict the biological success of drug compounds.…

Continue Reading

WednesdaySep 21, 2022 11:37 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has closed on its recent public offering. The offering was comprised of 3,333,333 shares of common stock or common stock equivalents; the offering also included warrants to purchase up to 3,333,333 shares of common stock. The combined offering price to the public was $6 per share and associated warrant, with the warrants, which are exercisable upon being issued, having an exercise price of $6 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering, which resulted…

Continue Reading

TuesdaySep 20, 2022 3:21 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Releases New Video Exploring Its Technologies, Progress of AIMIGo(TM) Device

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. The company today announced that, in conjunction with its upcoming virtual roadshow webinar taking place at 4:30 p.m. ET on Tuesday, Sept. 20, 2022, it has released a new video that takes viewers behind the scenes for a featured look at the HeartBeam AIMIGo technology. “This new video provides a compelling overview and explanation of our technologies and highlights our continued progress toward making the AIMIGo device available for remote heart attack detection,” said Branislav Vajdic,…

Continue Reading

TuesdaySep 20, 2022 1:43 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached faster than expected, and have helped Cybin make progress on its path toward clinical drug development. The milestones were key in moving Cybin’s psychedelic programs from lab to clinic and have enabled the company to discover potential new drug formulations and delivery methods as well as create clinical protocols for psychedelic compounds and support clinical-stage development of CYBN’s proprietary CYB003…

Continue Reading

TuesdaySep 20, 2022 10:39 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, will be releasing its financial report for fiscal year 2022, the period ended June 30, 2022, later this month. The company has announced that it will release the financial report, along with business highlights, on Sept. 23, 2022. In addition, the company has announced a conference call and webcast to be held the same day at 1 p.m. ET. Those interested in listening in on the conference call can register for the call; they will then receive information about how to dial in to the…

Continue Reading

FridaySep 16, 2022 2:11 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares of its common stock. According to the announcement, the combined offering price will be $6 per share (or common stock equivalent) and associated warrants. The company noted that in addition to the $6 per share exercise price, the warrants will be immediately exercisable with an…

Continue Reading

FridaySep 16, 2022 1:45 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (‘NBTS’) estimates that over 10,000 individuals with GBM succumb to the disease annually. GBM has a five-year survival rate of…

Continue Reading

ThursdaySep 15, 2022 3:05 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting

Silo Pharma (OTCQB: SILOD), a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it will effect a 1-for-50 reverse split of its common stock. Effective at the open of business on Thursday, Sept. 15, 2022, the reverse stock split is in preparation for the planned listing of the company’s securities on the Nasdaq Capital Market (“Nasdaq”). The company’s common stock has begun trading on the OTC Markets system on a split-adjusted basis under the temporary ticker symbol SILOD. The fifth character “D” will remain appended to Silo Pharma’s symbol for 20 business days or…

Continue Reading

ThursdaySep 15, 2022 11:52 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures Additional IP Protection for Breakthrough ECG Patch Technology

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced issuance of its patent for a 12-lead electrocardiogram (“ECG”) patch monitor intended for detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia by the United States Patent and Trademark Office. According to the update, the innovation builds on HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting. “This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple…

Continue Reading

WednesdaySep 14, 2022 12:36 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a ‘may proceed’ letter and Investigational New Drug Application (‘IND’) clearance from the U.S.…

Continue Reading